A massive Korean study tracking 8,561 colorectal cancer patients has delivered a surprisingly precise answer – age 70 marks the cutoff where a standard chemotherapy drug loses its lifesaving power. Researchers analyzed national health records spanning three years to determine whether oxaliplatin, a cornerstone of colorectal cancer treatment, provides survival benefits across different age groups. Colorectal cancer rates continue climbing among older adults, making treatment optimization critical for both patient outcomes and resource allocation. The study’s size and scope – encompassing virtually all colorectal cancer patients treated in South Korea during the study period – lends exceptional weight to its conclusions. As cancer treatment increasingly emphasizes precision medicine, age 70 has emerged as a critical dividing line that could guide treatment decisions for years to come.